VIDAS RUB IgG (RBG), REF 30226
Published January 5, 2022 · Recall initiated: September 22, 2021
Summary
FDA records medical device Class II recall Z-0432-2022, published January 5, 2022 and initiated September 22, 2021. Recalling firm: bioMerieux, Inc.; Status: Ongoing; Reported quantity: Three lots; Lot: UDI 03573026138585, Lot #: 1008694980, 1008700260, 1008828980. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- bioMerieux, Inc.
- Distributor
- US Nationwide distribution.
- Lot
- UDI 03573026138585, Lot #: 1008694980, 1008700260, 1008828980
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAVITEK 2 Systems and VITEK 2 with MYLA.May 18, 2022
- FDAGiant Eagle, Diced Green Peppers, 10 oz. poly bags and 22# cases, also poly bags and cartons, 12/10 oz. bagsJanuary 5, 2022
- FDAARTISTE with syngo RT Therapist-linear accelerator systems to deliver X-Ray photon and electron radiation forJanuary 5, 2022
- FDAVITEK® 2 Systems Software Version 9.01 Update Kit.December 26, 2018
- FDABACT/ALERT VIRTUO system, B Unit, with Version R2.0 Firmware Product Usage: The BacT/ALERT VIRTU MicrobialOctober 31, 2018
- FDAVITEK(R) 2 AST-P655, For susceptibility testing of Staphylococcus spp. Enterococcus spp., ad S agalactiaeSeptember 26, 2018
Questions about this recall
Was VIDAS RUB IgG (RBG), REF 30226 recalled?
Yes. FDA published recall Z-0432-2022 on January 5, 2022. Reported hazard: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail